Shenzhen YHLO Biotech (SHA:688575) obtained medical device registration from the Guangdong regulator for its soluble CD146 chemiluminescence detection kit, according to a Tuesday filing with the Shanghai bourse.
The test aids in diagnosing central nervous system inflammatory demyelinating diseases, autoimmune encephalitis spectrum disorders and infectious diseases of the central nervous system.
Shares of the biotechnology company closed 1% lower Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.